Last updated on February 2018

High-Dose Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs


Brief description of study

the purpose of this study is to evaluate the efficacy and safety of high-dosepulsatile Erlotinib/Gefitinib in advanced non small cell lung cancer (NSCLC) patients after failure of standard dose EGFR-TKIsEpidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Detailed Study Description

To evaluate the efficacy and safety by treating the advanced non small cell lung cancer (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)

Clinical Study Identifier: NCT01965275

Contact Investigators or Research Sites near you

Start Over

Yueyin Pan, MD

Dept. of Oncology,The First Affiliated Hospital of Anhui Medical Univesrsity
Hefei, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.